| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US7235576 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124630 | BAYER HLTHCARE | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US7897623 | BAYER HLTHCARE | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US8841330 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(4 years ago) | |
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(1 year, 2 months ago) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(4 years from now) | |
Nexavar is owned by Bayer Hlthcare.
Nexavar contains Sorafenib Tosylate.
Nexavar has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Nexavar are:
- US8124630
- US7897623
- US8841330
- US8618141
- US7351834
- US7235576
Nexavar was authorised for market use on 20 December, 2005.
Nexavar is available in tablet;oral dosage forms.
Nexavar can be used as treatment of advanced renal cell carcinoma, treatment of unresectable hepatocellular carcinoma, treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma., treatment of carcinoma of the thyroid.
The generics of Nexavar are possible to be released after 10 September, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Treatment: Treatment of carcinoma of the thyroid; Treatment of unresectable hepatocellular carcinoma; Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced rena...
Dosage: TABLET;ORAL
NEXAVAR family patents
